Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Trastuzumab-anns |
| Trade Name | Kanjinti |
| Synonyms | ABP 980 |
| Drug Descriptions |
Kanjinti (Trastuzumab-anns) is a Herceptin (trastuzumab) biosimilar that binds to Erbb2 (Her2), which potentially results in anti-tumor immune response against Erbb2 (Her2)-positive tumors (PMID: 31798693). Kanjinti (Trastuzumab-anns) is FDA approved for use in patients with Erbb2 (Her2) overexpressing breast, metastatic gastric or gastroesophageal junction adenocarcinoma (FDA.gov). |
| DrugClasses | HER2 (ERBB2) Antibody 79 |
| CAS Registry Number | 1446410-98-5 |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + Docetaxel + Trastuzumab-anns | Carboplatin Docetaxel Trastuzumab-anns | 0 | 0 |
| Docetaxel + Trastuzumab-anns | Docetaxel Trastuzumab-anns | 0 | 0 |
| Paclitaxel + Trastuzumab-anns | Paclitaxel Trastuzumab-anns | 0 | 0 |
| Trastuzumab-anns | Trastuzumab-anns | 0 | 0 |